Analysts expect Aditxt Inc. to report a significant Q2 2026 loss of approximately $412.84 per share on estimated revenue of $1.00 million, while the stock trades at $0.0026 against a $61.00 average analyst target. The central story for investors is the company's critical 'going concern' status as it faces a massive equity deficit and severe liquidity constraints. Recent filings revealed a $35 million stockholders' equity deficit and less than $300,000 in cash, leading to substantial doubt about its operational survival. Following the termination of major acquisition agreements with Appili Therapeutics and Evofem Biosciences, investors are looking for any sign of a sustainable financing strategy or strategic pivot.